UTHR director exercises options, sells 1,000 shares

UNITED THERAPEUTICS Corp director Christopher Causey reported option exercises and a share sale.

Accepted by SEC EDGAR 02/25/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Christopher Causey reported option exercises and a share sale. He exercised stock options for 1,000 shares on February 25, 2026, converting derivative securities at a stated price of $0.0000 and acquiring 1,000 shares of common stock at $119.7600 per share.

On the same date, he sold 1,000 shares of common stock at $520.0000 per share in an open-market transaction. After these transactions, he directly held 4,190 shares of common stock and 6,320 stock options. The exercise and subsequent sale were made under a Rule 10b5-1 trading plan entered into on September 30, 2025.

Insider Trade Summary

Exercise and Sale: 1,000 shares ($400K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider CAUSEY CHRISTOPHER

Role Director

Sold 1,000 shs ($520K)

Approx. gross sale proceeds $520K

Approx. exercise cost $120K

Approx. pre-tax spread $400K

Type	Security	Shares	Price	Value
Exercise	Stock Option	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$119.76	$120K
Sale	Common Stock	1,000	$520.00	$520K

Holdings After Transaction: Stock Option — 6,320 contracts (Direct); Common Stock — 4,190 shares (Direct)

Footnotes (1)

1. F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Christopher Causey report for UNITED THERAPEUTICS (UTHR)?

Christopher Causey reported exercising stock options and selling shares of UNITED THERAPEUTICS common stock. On February 25, 2026, he exercised options for 1,000 shares and sold 1,000 shares in an open-market transaction, all under a pre-established Rule 10b5-1 trading plan.

How many UNITED THERAPEUTICS (UTHR) shares did Christopher Causey sell?

Christopher Causey sold 1,000 shares of UNITED THERAPEUTICS common stock. The sale occurred on February 25, 2026, at a reported price of $520.0000 per share in an open-market or private transaction, following the exercise of stock options for the same number of shares.

At what prices did Christopher Causey exercise and sell UTHR shares?

Christopher Causey exercised stock options at a stated price of $0.0000 and acquired 1,000 UNITED THERAPEUTICS shares valued at $119.7600 per share. He then sold 1,000 common shares at $520.0000 per share on February 25, 2026, in an open-market transaction.

How many UNITED THERAPEUTICS (UTHR) shares does Christopher Causey hold after the Form 4 transactions?

After the reported transactions, Christopher Causey directly holds 4,190 shares of UNITED THERAPEUTICS common stock. He also holds 6,320 stock options following the derivative exercise on February 25, 2026, as disclosed in the Form 4 ownership balances.

Was Christopher Causey’s UNITED THERAPEUTICS (UTHR) trade under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states that the option exercise and subsequent share sale were executed under a Rule 10b5-1 trading plan. This plan was entered into by Christopher Causey on September 30, 2025, before the February 25, 2026 transactions.

What is the net share change from Christopher Causey’s UTHR Form 4 transactions?

The Form 4 summary shows a net-sell direction of 1,000 shares. Causey exercised options and acquired 1,000 shares, then sold 1,000 shares, resulting in 1,000 shares sold on a net basis relative to open-market activity, while his option holdings increased.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAUSEY CHRISTOPHER

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		M(1)		1,000	A	$119.76	5,190	D
Common Stock	02/25/2026		S(1)		1,000	D	$520	4,190	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$119.76	02/25/2026		M(1)			1,000	06/26/2021	06/26/2030	Common Stock	1,000	$0.00	6,320	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.